Compare Howmet Aerospace Inc (HWM) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Howmet Aerospace Inc vs Neurocrine Biosciences Inc — how do they compare? Howmet Aerospace Inc trades at $279 (market cap $108.82B), while Neurocrine Biosciences Inc trades at $179.87 (market cap $17.40B). The key difference: Howmet Aerospace Inc is far larger — about 6.3× Neurocrine Biosciences Inc's market cap, and Howmet Aerospace Inc pays a 0.18% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| HWM | NBIX | |
|---|---|---|
Market Cap | $108.82B | $17.40B |
Sector | Industrials | Health |
52-Week High | $283.23 | $180.55 |
52-Week Low | $171.00 | $123.10 |
Enterprise Value | $111.07B | $16.49B |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Howmet Aerospace (HWM) trades at $271.98, down 0.17% on the day, with a neutral technical signal and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.22 exceeding the $1.11 estimate. Financials show robust profitability, including a 20.22% net income margin and 33.98% ROE, though valuation ratios like a P/E of 63.21 appear elevated. Recent news highlights commercial aerospace demand driving growth, with shares gaining 249% since May 2024 according to FXEmpire on July 15, 2026.
The outlook remains positive due to sustained aerospace demand and analyst consensus favoring buys, but risks include high valuation sensitivity and market volatility. Upside to the $317.63 price target offers potential, yet investors should weigh premium multiples against earnings growth momentum and sector cyclicality.
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% with strong bullish momentum. Recent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, underscore robust growth. The stock shows bullish technical signals with support at $170 and resistance at $173. Revenue growth accelerated to $2.86 billion in 2025, with net income margin improving to 21.55% in 2026 projections. Positive news highlights pipeline advancements and the Soleno acquisition.
Outlook remains positive with a consensus price target of $196.08, implying 13% upside. Key opportunities include sustained earnings growth and pipeline expansion, while risks involve clinical trial outcomes and competitive pressures. Institutional sentiment is strongly bullish with 86% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Howmet Aerospace Inc
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
